GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spago Nanomedical AB (OSTO:SPAGO) » Definitions » Revenue

Spago Nanomedical AB (OSTO:SPAGO) Revenue : kr1.47 Mil (TTM As of Mar. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Spago Nanomedical AB Revenue?

Spago Nanomedical AB's revenue for the three months ended in Mar. 2024 was kr0.35 Mil. Its revenue for the trailing twelve months (TTM) ended in Mar. 2024 was kr1.47 Mil. Spago Nanomedical AB's Revenue per Share for the three months ended in Mar. 2024 was kr0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was kr0.01.

Warning Sign:

Spago Nanomedical AB revenue per share has been in decline over the past 3 years.

During the past 12 months, the average Revenue per Share Growth Rate of Spago Nanomedical AB was -28.60% per year. During the past 3 years, the average Revenue per Share Growth Rate was -2.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Spago Nanomedical AB's highest 3-Year average Revenue per Share Growth Rate was 152.00% per year. The lowest was -86.40% per year. And the median was -26.30% per year.


Spago Nanomedical AB Revenue Historical Data

The historical data trend for Spago Nanomedical AB's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spago Nanomedical AB Revenue Chart

Spago Nanomedical AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 0.34 0.66 1.05 1.20

Spago Nanomedical AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 0.11 0.27 0.73 0.35

Competitive Comparison of Spago Nanomedical AB's Revenue

For the Biotechnology subindustry, Spago Nanomedical AB's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spago Nanomedical AB's Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spago Nanomedical AB's Revenue distribution charts can be found below:

* The bar in red indicates where Spago Nanomedical AB's Revenue falls into.



Spago Nanomedical AB Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr1.47 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Spago Nanomedical AB  (OSTO:SPAGO) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Spago Nanomedical AB Revenue Related Terms

Thank you for viewing the detailed overview of Spago Nanomedical AB's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Spago Nanomedical AB (OSTO:SPAGO) Business Description

Traded in Other Exchanges
Address
Scheelevagen 22, Lund, SWE, SE-223 63
Spago Nanomedical AB is a nanomedicine company in the field of cancer diagnosis and treatment. The company's product includes SpagoPix and Tumorad. The SpagoPix product aims to improve cancer diagnosis with magnetic resonance imaging through previous detection of tumors and metastases. The Tumorad products focuses on the development of a completely new form of radionuclide therapy for tumor selective radiation therapy of cancer. The company development projects are based on a platform of polymeric materials with varoious properties for precise diagnosis and treatment of life threatening and debilitating diseases.

Spago Nanomedical AB (OSTO:SPAGO) Headlines

No Headlines